Ana Luisa Godoy Fernandes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ana Luisa Godoy Fernandes has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
- Ilka Lopes Santoro
Disciplina de Pneumologia, Universidade Federal de São Paulo - UNIFESP - São Paulo (SP) Brasil
22 shared publications - Maria Alenita de Oliveira
Universidade Federal da Paraíba João Pessoa, Brasil
11 shared publications - Juliana Pereira Franceschini
Disciplina de Pneumologia, Universidade Federal de São Paulo - UNIFESP - São Paulo (SP) Brasil
6 shared publications Lilian Ballini Caetano
5 shared publications- Maria Marta Amorim
Division of Respiratory Medicine, Department of Medicine, Universidade Federal de São Paulo, São Paulo 04024-002, Brazil
4 shared publications Sonia Maria Faresin
4 shared publications
Latest Publications
- Open Access
- 10 December 2025
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (12) , 615
Asthma-Associated COPD Etiotype: Clinical Features and Inflammatory Patterns in Biological Samples
Background: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recognizes asthma as a potential causal pathway for chronic obstructive pulmonary disease, referred to as the COPD-A etiotype. However, the clinical and inflammatory characteristics of this phenotype remain poorly defined. Objectives: This study aimed to characterize clinical traits and cytokine profiles in stable asthmatics exhibiting persistent airflow limitation compatible with COPD-A. Methods: In this cross-sectional study, 94 stable asthmatic patients (71.3% female; age = 54.0 ± 15.6 years) without relevant smoking or environmental exposures were evaluated. COPD-A was defined by a post-bronchodilator FEV1/FVC ratio < 0.70. Asthma control (ACQ, ACT), quality of life (AQLQ), and lung function were assessed. Levels of IL-5, IL-8, IL-13, IL-17A, IL-17F, IL-25, IL-33, and TNF were quantified in nasal lavage, induced sputum, and blood samples. Results: Among the participants, 42 (44.7%) fulfilled COPD-A criteria. Compared with non-COPD-A subjects, those with COPD-A were older (60.5 vs. 48.7 years; p < 0.001) and had longer disease duration (39.8 vs. 30.1 years; p < 0.001), lower post-bronchodilator FEV1% predicted (68.1 vs. 87.1%; p < 0.001), and poorer asthma control (ACQ = 1.00 vs. 0.64; p = 0.003). Cytokine levels were comparable between groups except for higher IL-8 concentrations in induced sputum of COPD-A subjects (7.66 vs. 2.51 pg/mL; p = 0.024). Sputum IL-8 ≥ 3.096 pg/mL independently predicted COPD-A (aOR = 12.82; p = 0.023). Conclusions: Over 40% of non-smoking asthmatics exhibited persistent airflow limitation consistent with COPD-A. Elevated sputum IL-8 levels may be a potential biomarker of this etiotype.
- 10 December 2025
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (12) , 615
Open AccessAsthma-Associated COPD Etiotype: Clinical Features and Inflammatory Patterns in Biological Samples
Background: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recognizes asthma as a potential causal pathway for chronic obstructive pulmonary disease, referred to as the COPD-A etiotype. However, the clinical and inflammatory characteristics of this phenotype remain poorly defined. Objectives: This study aimed to characterize clinical traits and cytokine profiles in stable asthmatics exhibiting persistent airflow limitation compatible with COPD-A. Methods: In this cross-sectional study, 94 stable asthmatic patients (71.3% female; age = 54.0 ± 15.6 years) without relevant smoking or environmental exposures were evaluated. COPD-A was defined by a post-bronchodilator FEV1/FVC ratio < 0.70. Asthma control (ACQ, ACT), quality of life (AQLQ), and lung function were assessed. Levels of IL-5, IL-8, IL-13, IL-17A, IL-17F, IL-25, IL-33, and TNF were quantified in nasal lavage, induced sputum, and blood samples. Results: Among the participants, 42 (44.7%) fulfilled COPD-A criteria. Compared with non-COPD-A subjects, those with COPD-A were older (60.5 vs. 48.7 years; p < 0.001) and had longer disease duration (39.8 vs. 30.1 years; p < 0.001), lower post-bronchodilator FEV1% predicted (68.1 vs. 87.1%; p < 0.001), and poorer asthma control (ACQ = 1.00 vs. 0.64; p = 0.003). Cytokine levels were comparable between groups except for higher IL-8 concentrations in induced sputum of COPD-A subjects (7.66 vs. 2.51 pg/mL; p = 0.024). Sputum IL-8 ≥ 3.096 pg/mL independently predicted COPD-A (aOR = 12.82; p = 0.023). Conclusions: Over 40% of non-smoking asthmatics exhibited persistent airflow limitation consistent with COPD-A. Elevated sputum IL-8 levels may be a potential biomarker of this etiotype.
- Open Access
- 20 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (6) , 3501
Exploring Inflammatory Asthma Phenotypes: Proteomic Signatures in Serum and Induced Sputum
Asthma drug responses may differ due to inflammatory mechanisms triggered by the immune cells in the pulmonary microenvironment. Thus, asthma phenotyping based on the local inflammatory profile may aid in treatment definition and the identification of new therapeutic targets. Here, we investigated protein profiles of induced sputum and serum from asthma patients classified into eosinophilic, neutrophilic, mixed granulocytic, and paucigranulocytic asthma, according to inflammatory phenotypes. Proteomic analyses were performed using an ultra-performance liquid chromatography (ultra-HPLC) system coupled to the Q Exactive Hybrid Quadrupole Orbitrap Mass Spectrometer. Fifty-two (52) proteins showed significant differences in induced sputum among the groups, while only 12 were altered in patients’ sera. Five proteins in the induced sputum were able to discriminate all phenotypic groups, while four proteins in the serum could differentiate all except the neutrophilic from the paucigranulocytic inflammatory pattern. This is the first report on comparative proteomics of inflammatory asthma phenotypes in both sputum and serum samples. We have identified a potential five-biomarker panel that may be able to discriminate all four inflammatory phenotypes in sputum. These findings not only provide insights into potential therapeutic targets but also emphasize the potential for personalized treatment approaches in asthma management.
- 20 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (6) , 3501
Open AccessExploring Inflammatory Asthma Phenotypes: Proteomic Signatures in Serum and Induced Sputum
Asthma drug responses may differ due to inflammatory mechanisms triggered by the immune cells in the pulmonary microenvironment. Thus, asthma phenotyping based on the local inflammatory profile may aid in treatment definition and the identification of new therapeutic targets. Here, we investigated protein profiles of induced sputum and serum from asthma patients classified into eosinophilic, neutrophilic, mixed granulocytic, and paucigranulocytic asthma, according to inflammatory phenotypes. Proteomic analyses were performed using an ultra-performance liquid chromatography (ultra-HPLC) system coupled to the Q Exactive Hybrid Quadrupole Orbitrap Mass Spectrometer. Fifty-two (52) proteins showed significant differences in induced sputum among the groups, while only 12 were altered in patients’ sera. Five proteins in the induced sputum were able to discriminate all phenotypic groups, while four proteins in the serum could differentiate all except the neutrophilic from the paucigranulocytic inflammatory pattern. This is the first report on comparative proteomics of inflammatory asthma phenotypes in both sputum and serum samples. We have identified a potential five-biomarker panel that may be able to discriminate all four inflammatory phenotypes in sputum. These findings not only provide insights into potential therapeutic targets but also emphasize the potential for personalized treatment approaches in asthma management.
- Open Access
- 30 December 2021
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 47 (6) , e20210273
2021 Brazilian Thoracic Association recommendations for the management of severe asthma
Advances in the understanding that severe asthma is a complex and heterogeneous disease and in the knowledge of the pathophysiology of asthma, with the identification of different phenotypes and endotypes, have allowed new approaches for the diagnosis and characterization of the disease and have resulted in relevant changes in pharmacological management. In this context, the definition of severe asthma has been established, being differentiated from difficult-to-control asthma. These recommendations address this topic and review advances in phenotyping, use of biomarkers, and new treatments for severe asthma. Emphasis is given to topics regarding personalized management of the patient and selection of biologicals, as well as the importance of evaluating the response to treatment. These recommendations apply to adults and children with severe asthma and are targeted at physicians involved in asthma treatment. A panel of 17 Brazilian pulmonologists was invited to review recent evidence on the diagnosis and management of severe asthma, adapting it to the Brazilian reality. Each of the experts was responsible for reviewing a topic or question relevant to the topic. In a second phase, four experts discussed and structured the texts produced, and, in the last phase, all experts reviewed and approved the present manuscript and its recommendations.
- 30 December 2021
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 47 (6) , e20210273
Open Access2021 Brazilian Thoracic Association recommendations for the management of severe asthma
Advances in the understanding that severe asthma is a complex and heterogeneous disease and in the knowledge of the pathophysiology of asthma, with the identification of different phenotypes and endotypes, have allowed new approaches for the diagnosis and characterization of the disease and have resulted in relevant changes in pharmacological management. In this context, the definition of severe asthma has been established, being differentiated from difficult-to-control asthma. These recommendations address this topic and review advances in phenotyping, use of biomarkers, and new treatments for severe asthma. Emphasis is given to topics regarding personalized management of the patient and selection of biologicals, as well as the importance of evaluating the response to treatment. These recommendations apply to adults and children with severe asthma and are targeted at physicians involved in asthma treatment. A panel of 17 Brazilian pulmonologists was invited to review recent evidence on the diagnosis and management of severe asthma, adapting it to the Brazilian reality. Each of the experts was responsible for reviewing a topic or question relevant to the topic. In a second phase, four experts discussed and structured the texts produced, and, in the last phase, all experts reviewed and approved the present manuscript and its recommendations.
- 29 May 2020
- Published by Springer Nature
- p. 259-272
Central Sleep Apnoea Treatment: When and How?
- Open Access
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Jornal Brasileiro de Pneumologia
- Vol. 46 (1) , e20190307
2020 Brazilian Thoracic Association recommendations for the management of asthma
The pharmacological management of asthma has changed considerably in recent decades, as it has come to be understood that it is a complex, heterogeneous disease with different phenotypes and endotypes. It is now clear that the goal of asthma treatment should be to achieve and maintain control of the disease, as well as to minimize the risks (of exacerbations, disease instability, accelerated loss of lung function, and adverse treatment effects). That requires an approach that is personalized in terms of the pharmacological treatment, patient education, written action plan, training in correct inhaler use, and review of the inhaler technique at each office visit. A panel of 22 pulmonologists was invited to perform a critical review of recent evidence of pharmacological treatment of asthma and to prepare this set of recommendations, a treatment guide tailored to use in Brazil. The topics or questions related to the most significant changes in concepts, and consequently in the management of asthma in clinical practice, were chosen by a panel of experts. To formulate these recommendations, we asked each expert to perform a critical review of a topic or to respond to a question, on the basis of evidence in the literature. In a second phase, three experts discussed and structured all texts submitted by the others. That was followed by a third phase, in which all of the experts reviewed and discussed each recommendation. These recommendations, which are intended for physicians involved in the treatment of asthma, apply to asthma patients of all ages.
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Jornal Brasileiro de Pneumologia
- Vol. 46 (1) , e20190307
Open Access2020 Brazilian Thoracic Association recommendations for the management of asthma
The pharmacological management of asthma has changed considerably in recent decades, as it has come to be understood that it is a complex, heterogeneous disease with different phenotypes and endotypes. It is now clear that the goal of asthma treatment should be to achieve and maintain control of the disease, as well as to minimize the risks (of exacerbations, disease instability, accelerated loss of lung function, and adverse treatment effects). That requires an approach that is personalized in terms of the pharmacological treatment, patient education, written action plan, training in correct inhaler use, and review of the inhaler technique at each office visit. A panel of 22 pulmonologists was invited to perform a critical review of recent evidence of pharmacological treatment of asthma and to prepare this set of recommendations, a treatment guide tailored to use in Brazil. The topics or questions related to the most significant changes in concepts, and consequently in the management of asthma in clinical practice, were chosen by a panel of experts. To formulate these recommendations, we asked each expert to perform a critical review of a topic or to respond to a question, on the basis of evidence in the literature. In a second phase, three experts discussed and structured all texts submitted by the others. That was followed by a third phase, in which all of the experts reviewed and discussed each recommendation. These recommendations, which are intended for physicians involved in the treatment of asthma, apply to asthma patients of all ages.
- Open Access
- 1 August 2018
- Published by FapUNIFESP (SciELO) in Jornal Brasileiro de Pneumologia
- Vol. 44 (4) , 253
A teacher to remember and to emulate
It was common to hear Professor Santos say, “São Paulo owes a debt to the country. We must train pulmonologists as a group of critical thinkers who will disseminate knowledge throughout the country.” In addition to receiving students from other countries in Latin America, he taught students from every state in Brazil, making the EPM Discipline of Pulmonology the leading producer of pulmonology specialists in the country. He also actively collaborated in the development of the first graduate program in pulmonology in Brazil. His ability to impart knowledge was without par, due to the empathy he had for all who wanted to learn and work, as well as the unconditional love he had for the mission of teaching.
- 1 August 2018
- Published by FapUNIFESP (SciELO) in Jornal Brasileiro de Pneumologia
- Vol. 44 (4) , 253
Open AccessA teacher to remember and to emulate
It was common to hear Professor Santos say, “São Paulo owes a debt to the country. We must train pulmonologists as a group of critical thinkers who will disseminate knowledge throughout the country.” In addition to receiving students from other countries in Latin America, he taught students from every state in Brazil, making the EPM Discipline of Pulmonology the leading producer of pulmonology specialists in the country. He also actively collaborated in the development of the first graduate program in pulmonology in Brazil. His ability to impart knowledge was without par, due to the empathy he had for all who wanted to learn and work, as well as the unconditional love he had for the mission of teaching.
- 1 September 2017
- Published by European Respiratory Society (ERS)
- Vol. 50 (suppl 61) , PA4309
Malignant pleural mesothelioma:a 16-year, single centre experience
Background:Malignant pleural mesothelioma (MPM) is a rare and highly aggressive malignancy, primarily attributable to asbestos exposure. Aim:To report the experience of our centre in the management of MPM. Methods:All consecutive cases of MPM diagnosed in our centre between 2000 and 2016 were retrospectively reviewed. Clinical data were extracted from medical records. Results:During the study period, we identified 28 cases of MPM, 17 (60,7%) male, with median age at diagnosis of 76 years. Patients (Pts) were predominantly non-smokers (67,9%) and 13 (46,4%) reported previous asbestos exposure. Clinical presentation was mainly characterized by indolent dyspnea and constitutional symptoms. The most common radiological findings were unilateral pleural effusion in 21 Pts (75%) and pleural thickening in 16 Pts (57,1%). The average diagnostic delay was 2 months (up to 24 months) and 21 Pts (75%) presented with stage IV (TNM) disease. Epithelioid histologic subtype was identified in 21 Pts (75%). Therapeutic strategies included: prophylactic thoracic radiotherapy in 15 Pts (53,6%); best supportive care in 14 Pts (50%); chemotherapy in 13 Pts (46,4%); and multimodal therapy with extrapleural pneumonectomy in 1 Pt (3,6%).Median overall survival (OS) was 3,5 months (4,9 months in best supportive care group; 7 months in chemotherapy group; 10 months in multimodal therapy group).Two-year survival rate was 11%. Conclusions:In our cohort, MPM mainly affected non-smoking older men, presenting with non-specific symptoms and advanced stage disease. The outcomes were poor (median OS 4,9-10 months) in accordance with the literature. Raising awareness, early recognition and novel treatment options are necessary to improve the outcomes of MPM.
- 1 September 2017
- Published by European Respiratory Society (ERS)
- Vol. 50 (suppl 61) , PA4309
Malignant pleural mesothelioma:a 16-year, single centre experience
Background:Malignant pleural mesothelioma (MPM) is a rare and highly aggressive malignancy, primarily attributable to asbestos exposure. Aim:To report the experience of our centre in the management of MPM. Methods:All consecutive cases of MPM diagnosed in our centre between 2000 and 2016 were retrospectively reviewed. Clinical data were extracted from medical records. Results:During the study period, we identified 28 cases of MPM, 17 (60,7%) male, with median age at diagnosis of 76 years. Patients (Pts) were predominantly non-smokers (67,9%) and 13 (46,4%) reported previous asbestos exposure. Clinical presentation was mainly characterized by indolent dyspnea and constitutional symptoms. The most common radiological findings were unilateral pleural effusion in 21 Pts (75%) and pleural thickening in 16 Pts (57,1%). The average diagnostic delay was 2 months (up to 24 months) and 21 Pts (75%) presented with stage IV (TNM) disease. Epithelioid histologic subtype was identified in 21 Pts (75%). Therapeutic strategies included: prophylactic thoracic radiotherapy in 15 Pts (53,6%); best supportive care in 14 Pts (50%); chemotherapy in 13 Pts (46,4%); and multimodal therapy with extrapleural pneumonectomy in 1 Pt (3,6%).Median overall survival (OS) was 3,5 months (4,9 months in best supportive care group; 7 months in chemotherapy group; 10 months in multimodal therapy group).Two-year survival rate was 11%. Conclusions:In our cohort, MPM mainly affected non-smoking older men, presenting with non-specific symptoms and advanced stage disease. The outcomes were poor (median OS 4,9-10 months) in accordance with the literature. Raising awareness, early recognition and novel treatment options are necessary to improve the outcomes of MPM.
- Open Access
- 23 January 2017
- Published by FapUNIFESP (SciELO) in Jornal Brasileiro de Pneumologia
- Vol. 43 (1) , 18-23
Family caregiver burden: the burden of caring for lung cancer patients according to the cancer stage and patient quality of life
Objective: Patients with lung cancer experience different feelings and reactions, based on their family, social, cultural, and religious backgrounds, which are a source of great distress, not only for the patients but also for their family caregivers. This study aimed to evaluate the impact that lung cancer stage and quality of life (QoL) of lung cancer patients have on caregiver burden. Methods: This was a prospective cross-sectional study. Consecutive patient-caregiver dyads were selected and asked to complete the Hospital Anxiety and Depression Scale and the Medical Outcomes Study 36-item ShortForm Health Survey (SF-36). Family caregivers also completed the Caregiver Burden Scale. Group-based modeling was used in order to identify patients with early- or advanced-stage cancer (IA to IIIA vs. IIIB to IV) plus non-impaired or impaired QoL (SF36 total score > 50 vs. ≤ 50). Patient-caregiver dyads were stratified into four groups: early-stage cancer+non-impaired QoL; advanced-stage cancer+non-impaired QoL; early-stage cancer+impaired QoL; and advanced-stage cancer+impaired QoL. Results: We included 91 patient-caregiver dyads. The majority of the patients were male and heavy smokers. Family caregivers were younger and predominantly female. The burden, QoL, level of anxiety, and level of depression of caregivers were more affected by the QoL of the patients than by their lung cancer stage. The family caregivers of the patients with impaired QoL showed a higher median burden than did those of the patients with non-impaired QoL, regardless of disease stage. Conclusions: Caregiver burden is more affected by patient QoL than by lung cancer stage.
- 23 January 2017
- Published by FapUNIFESP (SciELO) in Jornal Brasileiro de Pneumologia
- Vol. 43 (1) , 18-23
Open AccessFamily caregiver burden: the burden of caring for lung cancer patients according to the cancer stage and patient quality of life
Objective: Patients with lung cancer experience different feelings and reactions, based on their family, social, cultural, and religious backgrounds, which are a source of great distress, not only for the patients but also for their family caregivers. This study aimed to evaluate the impact that lung cancer stage and quality of life (QoL) of lung cancer patients have on caregiver burden. Methods: This was a prospective cross-sectional study. Consecutive patient-caregiver dyads were selected and asked to complete the Hospital Anxiety and Depression Scale and the Medical Outcomes Study 36-item ShortForm Health Survey (SF-36). Family caregivers also completed the Caregiver Burden Scale. Group-based modeling was used in order to identify patients with early- or advanced-stage cancer (IA to IIIA vs. IIIB to IV) plus non-impaired or impaired QoL (SF36 total score > 50 vs. ≤ 50). Patient-caregiver dyads were stratified into four groups: early-stage cancer+non-impaired QoL; advanced-stage cancer+non-impaired QoL; early-stage cancer+impaired QoL; and advanced-stage cancer+impaired QoL. Results: We included 91 patient-caregiver dyads. The majority of the patients were male and heavy smokers. Family caregivers were younger and predominantly female. The burden, QoL, level of anxiety, and level of depression of caregivers were more affected by the QoL of the patients than by their lung cancer stage. The family caregivers of the patients with impaired QoL showed a higher median burden than did those of the patients with non-impaired QoL, regardless of disease stage. Conclusions: Caregiver burden is more affected by patient QoL than by lung cancer stage.
- Open Access
- 29 November 2016
- Published by Wiley in Respirology
- Vol. 22 (4) , 671-677
Nasal lavage, blood or sputum: Which is best for phenotyping asthma?
Background and objective: Determination of asthma phenotypes, particularly inflammatory phenotypes, helps guide treatment and management of this heterogeneous disease. Induced sputum cytology has been the gold standard for determination of inflammatory phenotypes, but sputum induction is fairly invasive and technically challenging. Blood and nasal lavage cytology have been suggested as substitutes, but have not been fully verified. The aim of this study is to determine the accuracy of blood and nasal lavage cytometry as indicators of inflammatory phenotypes in asthma.Methods: Clinical evaluation, Asthma Control Questionnaire (ACQ) and spirometry were performed for 121 adult asthma patients, and blood, nasal lavage and induced sputum samples were taken. Eosinophils and neutrophils were counted in three samples from each subject. Inflammatory phenotypes (eosinophilic, neutrophilic, mixed and paucicellular) and cells counts were analysed using Venn diagram and receiver operating characteristic (ROC) curve, respectively.Results: ACQ score, spirometry and bronchodilator response did not differ among subjects with different inflammatory phenotypes. Inflammatory phenotypes defined by nasal lavage cytometry were in better concordance than those defined by blood cell counts with phenotypes determined by sputum cytology, and were significantly correlated with sputum phenotypes. For eosinophilia, nasal lavage cytology showed better accuracy than blood cytology (area under the curve (AUC): 0.89 vs 0.65). For all phenotypes, sensitivity and positive and negative predictive power were higher for nasal lavage cytometry than for blood. Blood cell counts gave a high level of false positives for all inflammatory phenotypes.Conclusion: We recommend nasal lavage cytology over blood cell count as a substitute for sputum cytology to identify inflammatory phenotypes in asthma.
- 29 November 2016
- Published by Wiley in Respirology
- Vol. 22 (4) , 671-677
Open AccessNasal lavage, blood or sputum: Which is best for phenotyping asthma?
Background and objective: Determination of asthma phenotypes, particularly inflammatory phenotypes, helps guide treatment and management of this heterogeneous disease. Induced sputum cytology has been the gold standard for determination of inflammatory phenotypes, but sputum induction is fairly invasive and technically challenging. Blood and nasal lavage cytology have been suggested as substitutes, but have not been fully verified. The aim of this study is to determine the accuracy of blood and nasal lavage cytometry as indicators of inflammatory phenotypes in asthma.Methods: Clinical evaluation, Asthma Control Questionnaire (ACQ) and spirometry were performed for 121 adult asthma patients, and blood, nasal lavage and induced sputum samples were taken. Eosinophils and neutrophils were counted in three samples from each subject. Inflammatory phenotypes (eosinophilic, neutrophilic, mixed and paucicellular) and cells counts were analysed using Venn diagram and receiver operating characteristic (ROC) curve, respectively.Results: ACQ score, spirometry and bronchodilator response did not differ among subjects with different inflammatory phenotypes. Inflammatory phenotypes defined by nasal lavage cytometry were in better concordance than those defined by blood cell counts with phenotypes determined by sputum cytology, and were significantly correlated with sputum phenotypes. For eosinophilia, nasal lavage cytology showed better accuracy than blood cytology (area under the curve (AUC): 0.89 vs 0.65). For all phenotypes, sensitivity and positive and negative predictive power were higher for nasal lavage cytometry than for blood. Blood cell counts gave a high level of false positives for all inflammatory phenotypes.Conclusion: We recommend nasal lavage cytology over blood cell count as a substitute for sputum cytology to identify inflammatory phenotypes in asthma.
- Open Access
- 1 October 2015
- Published by FapUNIFESP (SciELO) in Archives of Clinical Psychiatry (São Paulo)
- Vol. 42 (5) , 122-128
A psychiatric perspective view of bariatric surgery patients
Background Bariatric surgery is the only procedure that has significant results in weight loss and improvements in medical comorbidities in morbid obese patients. Severely obese patients are also associated with a higher prevalence of psychiatric disorders and poor quality of life. Objective To evaluate specific areas of psychopathology in individuals undergoing bariatric surgery. Methods A review of the literature was conducted from January 2002 to March 2014 by researching PubMed database using the following query: “morbid AND obesity AND bariatric AND surgery AND (psychiatry OR psychology)”. Results Overall improvements in eating behaviors, mood disorders and body image are reported after bariatric surgery, and the mechanism is not enlightened. Risk of suicide and consumption of substances of abuse, especially alcohol, after gastric bypass surgery are problems that clinicians must be aware. Discussion Bariatric patients should be monitored after surgery to identify who did not show the expected benefits postoperatively and the ones who develop psychiatric symptoms after an initial positive response.
- 1 October 2015
- Published by FapUNIFESP (SciELO) in Archives of Clinical Psychiatry (São Paulo)
- Vol. 42 (5) , 122-128
Open AccessA psychiatric perspective view of bariatric surgery patients
Background Bariatric surgery is the only procedure that has significant results in weight loss and improvements in medical comorbidities in morbid obese patients. Severely obese patients are also associated with a higher prevalence of psychiatric disorders and poor quality of life. Objective To evaluate specific areas of psychopathology in individuals undergoing bariatric surgery. Methods A review of the literature was conducted from January 2002 to March 2014 by researching PubMed database using the following query: “morbid AND obesity AND bariatric AND surgery AND (psychiatry OR psychology)”. Results Overall improvements in eating behaviors, mood disorders and body image are reported after bariatric surgery, and the mechanism is not enlightened. Risk of suicide and consumption of substances of abuse, especially alcohol, after gastric bypass surgery are problems that clinicians must be aware. Discussion Bariatric patients should be monitored after surgery to identify who did not show the expected benefits postoperatively and the ones who develop psychiatric symptoms after an initial positive response.